These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 11642306)
1. [STI571: the resistance organizes!]. Jeanteur P Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306 [No Abstract] [Full Text] [Related]
2. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Chien JH; Tang JL; Chen RL; Li CC; Lee CP Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297 [TBL] [Abstract][Full Text] [Related]
3. New-age drug meets resistance. McCormick F Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142 [No Abstract] [Full Text] [Related]
4. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? Goldman J Lab Hematol; 2004; 10(3):181-4. PubMed ID: 15529444 [No Abstract] [Full Text] [Related]
5. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391 [TBL] [Abstract][Full Text] [Related]
6. Roots of clinical resistance to STI-571 cancer therapy. Barthe C; Cony-Makhoul P; Melo JV; Mahon JR Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109 [No Abstract] [Full Text] [Related]
7. Roots of clinical resistance to STI-571 cancer therapy. Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495 [No Abstract] [Full Text] [Related]
8. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618 [TBL] [Abstract][Full Text] [Related]
9. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868 [No Abstract] [Full Text] [Related]
11. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia]. Tauchi T; Oyashiki K Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118 [No Abstract] [Full Text] [Related]
12. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211 [No Abstract] [Full Text] [Related]
13. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T Leukemia; 2006 Nov; 20(11):2057-60. PubMed ID: 17008892 [No Abstract] [Full Text] [Related]
14. Cancer treatment in the STI571 era: what will change? Sawyers CL J Clin Oncol; 2001 Sep; 19(18 Suppl):13S-16S. PubMed ID: 11560965 [No Abstract] [Full Text] [Related]
15. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases. Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300 [TBL] [Abstract][Full Text] [Related]
16. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia. Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834 [No Abstract] [Full Text] [Related]
18. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results]. Guilhot F Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817 [No Abstract] [Full Text] [Related]
19. Resistance and relapse with imatinib in CML: causes and consequences. Deininger M J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677 [TBL] [Abstract][Full Text] [Related]
20. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]